Version 1
: Received: 14 July 2023 / Approved: 14 July 2023 / Online: 17 July 2023 (15:06:14 CEST)
How to cite:
El Fazazi, I.; Ihlal, H.; Abbassi, M.; Ahakoud, M.; Nmer, S.; Bouguenouch, L.; Berrady, R.; Ouldim, K.; El-Azami El-Idrissi, M. Next Generation Sequencing in Diagnosis of Multiple Myeloma. Preprints2023, 2023071110. https://doi.org/10.20944/preprints202307.1110.v1
El Fazazi, I.; Ihlal, H.; Abbassi, M.; Ahakoud, M.; Nmer, S.; Bouguenouch, L.; Berrady, R.; Ouldim, K.; El-Azami El-Idrissi, M. Next Generation Sequencing in Diagnosis of Multiple Myeloma. Preprints 2023, 2023071110. https://doi.org/10.20944/preprints202307.1110.v1
El Fazazi, I.; Ihlal, H.; Abbassi, M.; Ahakoud, M.; Nmer, S.; Bouguenouch, L.; Berrady, R.; Ouldim, K.; El-Azami El-Idrissi, M. Next Generation Sequencing in Diagnosis of Multiple Myeloma. Preprints2023, 2023071110. https://doi.org/10.20944/preprints202307.1110.v1
APA Style
El Fazazi, I., Ihlal, H., Abbassi, M., Ahakoud, M., Nmer, S., Bouguenouch, L., Berrady, R., Ouldim, K., & El-Azami El-Idrissi, M. (2023). Next Generation Sequencing in Diagnosis of Multiple Myeloma. Preprints. https://doi.org/10.20944/preprints202307.1110.v1
Chicago/Turabian Style
El Fazazi, I., Karim Ouldim and Mohammed El-Azami El-Idrissi. 2023 "Next Generation Sequencing in Diagnosis of Multiple Myeloma" Preprints. https://doi.org/10.20944/preprints202307.1110.v1
Abstract
Multiple myeloma (MM) is an incurable, diverse cancer in which abnormal plasma cells produce and release monoclonal immunoglobulin (Ig), also known as monoclonal protein or M protein. MM is always preceded by monoclonal gammaglobulinemia of unknown significance (MGUS) and smoldering multiple myeloma (SMM). Diagnosis of MM is made from a bone marrow sample, which involves analysis of the appearance of plasma cells. Quantification of CD138+ plasma cells in core biopsies is performed using techniques such as immunohistochemistry, flow cytometry, fluorescence in situ hybridization (FISH) and conventional cytogenetics. Urinalysis includes total protein by immunofixation and 24-hour urine by serum protein electrophoresis. FISH probes should detect the presence of at least del 13, del 17p, t(4;14), t(11;14), t(14;16), and 1q21 amplifications. Indeed, next-generation sequencing (NGS) has become an increasingly important tool in the diagnosis and treatment of MM. It can be used to identify genetic mutations, copy number changes, and clonal structures to help determine disease prognosis and treatment strategies. NGS can identify subclonal populations of cancer cells that are resistant to therapy and may lead to disease relapse, and can be used to identify potential targets for personalized therapy. For example, NGS can identify mutations in genes involved in drug resistance, enabling the selection of drugs that may be more effective in treating a patient's cancer. This systematic review analyzes 182 papers to determine the position and role of NGS in the diagnosis of MM. We first analyze the platforms and sample types used in the selected studies, and then start discussing the results.
Biology and Life Sciences, Biochemistry and Molecular Biology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
